Where information overload has started to slow innovation and
efficiency in medicinal markets, could artificial intelligence and
machine learning help – by pinpointing what’s important and
suggesting better ways of doing things? Elvis Paćelat, Executive
Vice President, Life Sciences at AMPLEXOR, ponders the bigger
picture. In life sciences, start-ups are already using machine
learning algorithms to reduce drug discovery times; AI promises
to make clinical trials cheaper, faster and more targeted, offering
a way to find and keep teams focused on what’s important – from
what’s being said in the market, to how drugs are designed and